Novartis Ag (NVS) Liabilities and Shareholders Equity (2009 - 2026)

Novartis Ag has disclosed Liabilities and Shareholders Equity across 18 years of filings, most recently posting $122.0 billion for Q2 2026.

• In Q2 2026, Liabilities and Shareholders Equity rose 16.9% year-over-year to $122.0 billion; the TTM figure through Jun 2026 stood at $458.8 billion (up 11.87% YoY), while the FY2025 annual figure was $110.9 billion, up 8.51% from the prior year.
• Liabilities and Shareholders Equity came in at $122.0 billion for Q2 2026 at Novartis Ag, up from $118.5 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $125.2 billion in Q1 2022 to a low of $94.3 billion in Q1 2024.
• Average Liabilities and Shareholders Equity over 5 years is $110.0 billion, with a median of $111.0 billion recorded in 2023.
• Year-over-year, Liabilities and Shareholders Equity slipped 15.95% in 2024 and increased 18.6% in 2026.
• Over 5 years, Liabilities and Shareholders Equity stood at $117.5 billion in 2022, then declined by 14.91% to $99.9 billion in 2023, then advanced by 2.3% to $102.2 billion in 2024, then rose by 8.51% to $110.9 billion in 2025, then advanced by 9.99% to $122.0 billion in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $122.0 billion in Q2 2026, $118.5 billion in Q1 2026, and $110.9 billion in Q4 2025.